甲苯咪唑片中药物活性成分的晶型鉴别

目的：研究并快速鉴别甲苯咪唑片中活性组分的晶型特征。方法：利用甲苯咪唑不溶于水的特征，采用水洗去除制剂过程中添加的极性辅料，残渣经干燥后采用红外光谱扫描进行晶型的鉴别，并使用对甲苯咪唑晶型具有区分能力的溶出介质进一步验证。结果：目前国内外市场上的甲苯咪唑片中存在2种晶型，国内市场上甲苯咪唑片的原料均为有效晶型C；国外3家企业中有2家采用无效晶型A。结论：建立简便易行的方法测定制剂中甲苯咪唑的晶型，为监控甲苯咪唑片中的活性药用成分的晶型提供科学依据。

Objective: To investigate and identify the polymorphic forms of mebendazole in tablets. Methods: Using the water insoluble characteristic of mebendazole,the polar auxiliary material added during the preparation process in mebendazole tablets was removed by water washing. Then the residue dried was performed infrared scanning to identify the crystal forms;the crystal forms were further verified using a dissolution medium with a discriminating ability. Results: Two different crystal forms of mebendazole were observed. The raw materials of mebendazole tablets in the domestic market were all effective crystal C. Two of the three that from foreign enterprises adopted invalid crystal A. Conclusion: A simple and feasible method is established for the determination of the crystal forms of mebendazole in tablets,which can provide a scientific basis for monitoring the crystal forms of active medicinal ingredients in mebendazole tablets.

[1] RODRIGUEZ-CAABEIRO F,CRIADO-FORNELIO A,JIMENEZ-GONZALEZ A,et al. Experimental chemotherapy and toxicity in mice of three mebendazole polymorphic forms[J]. Chemotherapy,1987,33(4):266
[2] GARBUIO AQP,HANASHIRO T,MARKMAN BEO,et al. Evaluation and study of mebendazole polymorphs present in raw materials and tablets available in the Brazilian pharmaceutical market[J]. J Appl Pharm Sci,2014,4:1
[3] LIEBENBERG W,DEKKER TG,LOTTER AP,et al. Identification of the mebendazole polymorphic form present in raw materials and tablets available in South Africa[J]. Drug Dev Ind Pharm,1998,24(5):485
[4] 罗毅.药物多晶型的稳定性研究进展[J].中国医药导报,2009,28(6):5 LUO Yi. Research advancement on the stability of drug polymorphism[J]. China Med Her,2009,28(6):5
[5] 蔡紫阳,孙燕.多晶型药物研发及制剂最新研究进展[J].医药前沿,2012,41(36):12 CAI ZY,SUN Y. Recent advances in research and development of polymorphic drugs and preparations[J].Front Med,2012,41(36):12
[6] 侯鹏高,吕长淮.红外光谱法在药物制剂鉴别中的应用研究进展[J]. 中国医院药学杂志,2013,33(8):648. HOU PG,Lü CW. Advances in the application of infrared spectroscopy in the identification of pharmaceutical preparations[J]. Chin Hosp Pharm J,2013,33(8):648
[7] 岳志华,刘毅,张启明.关于《中国药典》制剂中采用红外光谱鉴别方法的讨论和建议[J]. 中国药品标准,2009,10(6):403 YUE ZH,LIU Y,ZHANG QM. Discussion and suggestion about identification of drug products using infrared spectrophotometers in Chinese Pharmacopoeia[J]. Drug Stand China,2009,10(6):403
[8] 徐皓,王化同,王洪莹. 红外吸收光谱在药物鉴别中的应用分析[J]. 中国卫生标准管理,2015,14(6):187 XU H,WANG HT,WANG HY. Analysis of the application of infrared spectroscopy in the identification of drugs[J].China Health Stand Manag,2015,14(6):187
[9] BRITS M,LIEBENBERG W,de VILLIERS MM. Characterization of polymorph transformations that decrease the stability of tablets containing the WHO essential drug mebendazole[J]. J Pharm Sci,2010,99(3):1138
[10] SWANEPOEL E,LIEBENBERG W,de VILLIERS MM. Quality evaluation of generic drugs by dissolution test:changing the USP dissolution medium to distinguish between active and non-active mebendazole polymorphs[J]. Eur J Pharm Biopharm,2003,55(3):345
[11] SWANEPOEL E,LIEBENBERG W,de VARAKONDA B,et al. Developing a discriminating dissolution test for three mebendazole polymorphs based on solubility differences[J]. Die Pharm,2003,58(2):117
[12] 中华人民共和国药典2015年版.二部[S].2015:200 ChP 2015.Vol Ⅱ[S].2015:200
[13] BP 20[S].2019:200
[14] EP 9.0[S].2017:2983
[15] USP 42-NF37[S].2019:2694
[16] InP 7[S].2017:1